<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39456680</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>20</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>10</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Implementation of an Immunoassay Based on the MVA-T7pol-Expression System for Rapid Identification of Immunogenic SARS-CoV-2 Antigens: A Proof-of-Concept Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">10898</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms252010898</ELocationID><Abstract><AbstractText>The emergence of hitherto unknown viral pathogens presents a great challenge for researchers to develop effective therapeutics and vaccines within a short time to avoid an uncontrolled global spread, as seen during the coronavirus disease 2019 (COVID-19) pandemic. Therefore, rapid and simple methods to identify immunogenic antigens as potential therapeutical targets are urgently needed for a better pandemic preparedness. To address this problem, we chose the well-characterized Modified Vaccinia virus Ankara (MVA)-T7pol expression system to establish a workflow to identify immunogens when a new pathogen emerges, generate candidate vaccines, and test their immunogenicity in an animal model. By using this system, we detected severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) nucleoprotein (N)-, and spike (S)-specific antibodies in COVID-19 patient sera, which is in line with the current literature and our observations from previous immunogenicity studies. Furthermore, we detected antibodies directed against the SARS-CoV-2-membrane (M) and -ORF3a proteins in COVID-19 patient sera and aimed to generate recombinant MVA candidate vaccines expressing either the M or ORF3a protein. When testing our candidate vaccines in a prime-boost immunization regimen in humanized <i>HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II</i>-knockout mice, we were able to demonstrate M- and ORF3a-specific cellular and humoral immune responses. Hence, the established workflow using the MVA-T7pol expression system represents a rapid and efficient tool to identify potential immunogenic antigens and provides a basis for future development of candidate vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Satendra</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7921-5746</Identifier><AffiliationInfo><Affiliation>Division of Virology, Department of Veterinary Sciences, Ludwig Maximilians University Munich (LMU Munich), 85764 Oberschleißheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nan</LastName><ForeName>Liangliang</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-7680-3630</Identifier><AffiliationInfo><Affiliation>Division of Virology, Department of Veterinary Sciences, Ludwig Maximilians University Munich (LMU Munich), 85764 Oberschleißheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalodimou</LastName><ForeName>Georgia</ForeName><Initials>G</Initials><Identifier Source="ORCID">0009-0002-5468-2695</Identifier><AffiliationInfo><Affiliation>Division of Virology, Department of Veterinary Sciences, Ludwig Maximilians University Munich (LMU Munich), 85764 Oberschleißheim, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Infection Research, Partner Site Munich, 85764 Oberschleißheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jany</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Virology, Department of Veterinary Sciences, Ludwig Maximilians University Munich (LMU Munich), 85764 Oberschleißheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freudenstein</LastName><ForeName>Astrid</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Virology, Department of Veterinary Sciences, Ludwig Maximilians University Munich (LMU Munich), 85764 Oberschleißheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brandmüller</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Virology, Department of Veterinary Sciences, Ludwig Maximilians University Munich (LMU Munich), 85764 Oberschleißheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Müller</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-2890-7515</Identifier><AffiliationInfo><Affiliation>German Center for Infection Research, Partner Site Munich, 85764 Oberschleißheim, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bundeswehr Institute of Microbiology, 80937 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Girl</LastName><ForeName>Philipp</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-1370-4114</Identifier><AffiliationInfo><Affiliation>German Center for Infection Research, Partner Site Munich, 85764 Oberschleißheim, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bundeswehr Institute of Microbiology, 80937 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chair of Bacteriology and Mycology, Department of Veterinary Sciences, Ludwig Maximilians University Munich (LMU Munich), 85764 Oberschleißheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ehmann</LastName><ForeName>Rosina</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>German Center for Infection Research, Partner Site Munich, 85764 Oberschleißheim, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bundeswehr Institute of Microbiology, 80937 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guggemos</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig Maximilians University Munich (LMU Munich), 80804 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seilmaier</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig Maximilians University Munich (LMU Munich), 80804 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wendtner</LastName><ForeName>Clemens-Martin</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Medical Clinic III, University Hospital, Ludwig Maximilians University Munich (LMU Munich), 80336 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volz</LastName><ForeName>Asisa</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8757-3896</Identifier><AffiliationInfo><Affiliation>Institute of Virology, University of Veterinary Medicine Hannover, 30559 Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Infection Research, Partner Site Hannover-Braunschweig, 30559 Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sutter</LastName><ForeName>Gerd</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-6143-082X</Identifier><AffiliationInfo><Affiliation>Division of Virology, Department of Veterinary Sciences, Ludwig Maximilians University Munich (LMU Munich), 85764 Oberschleißheim, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Infection Research, Partner Site Munich, 85764 Oberschleißheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fux</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1149-1613</Identifier><AffiliationInfo><Affiliation>Division of Virology, Department of Veterinary Sciences, Ludwig Maximilians University Munich (LMU Munich), 85764 Oberschleißheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tscherne</LastName><ForeName>Alina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Virology, Department of Veterinary Sciences, Ludwig Maximilians University Munich (LMU Munich), 85764 Oberschleißheim, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Infection Research, Partner Site Munich, 85764 Oberschleißheim, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F.2-F2412.32/1/45</GrantID><Agency>Bayerischer Forschungsverbund FOR-COVID</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086462">Coronavirus Nucleocapsid Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014616" MajorTopicYN="Y">Vaccinia virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="Y">Antigens, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000075082" MajorTopicYN="Y">Proof of Concept Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007118" MajorTopicYN="N">Immunoassay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086462" MajorTopicYN="N">Coronavirus Nucleocapsid Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MVA-T7pol</Keyword><Keyword MajorTopicYN="N">ORF3a protein</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">immunoassay</Keyword><Keyword MajorTopicYN="N">membrane protein</Keyword><Keyword MajorTopicYN="N">pandemic preparedness</Keyword><Keyword MajorTopicYN="N">rapid detection</Keyword><Keyword MajorTopicYN="N">visualization</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39456680</ArticleId><ArticleId IdType="pmc">PMC11508112</ArticleId><ArticleId IdType="doi">10.3390/ijms252010898</ArticleId><ArticleId IdType="pii">ijms252010898</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hadj Hassine I. COVID-19 vaccines and variants of concern: A review. Rev. Med. Virol. 2021;32:e2313. doi: 10.1002/rmv.2313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2313</ArticleId><ArticleId IdType="pmc">PMC8646685</ArticleId><ArticleId IdType="pubmed">34755408</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav T., Kumar S., Mishra G., Saxena S.K. Tracking the COVID-19 vaccines: The global landscape. Hum. Vaccines Immunother. 2023;19:2191577. doi: 10.1080/21645515.2023.2191577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2023.2191577</ArticleId><ArticleId IdType="pmc">PMC10101659</ArticleId><ArticleId IdType="pubmed">36995773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn W.O., Wiley Z. COVID-19 Vaccines. Infect. Dis. Clin. N. Am. 2022;36:481–494. doi: 10.1016/j.idc.2022.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idc.2022.01.008</ArticleId><ArticleId IdType="pmc">PMC8802612</ArticleId><ArticleId IdType="pubmed">35636910</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiolet T., Kherabi Y., MacDonald C.-J., Ghosn J., Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review. Clin. Microbiol. Infect. 2021;28:202–221. doi: 10.1016/j.cmi.2021.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.10.005</ArticleId><ArticleId IdType="pmc">PMC8548286</ArticleId><ArticleId IdType="pubmed">34715347</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillary V.E., Ceasar S.A. An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. Heliyon. 2023;9:e13952. doi: 10.1016/j.heliyon.2023.e13952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2023.e13952</ArticleId><ArticleId IdType="pmc">PMC9946785</ArticleId><ArticleId IdType="pubmed">36855648</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng B., Gao L., Zhou Q., Yu K., Sun F. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: A systematic review and meta-analysis. BMC Med. 2022;20:200. doi: 10.1186/s12916-022-02397-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-022-02397-y</ArticleId><ArticleId IdType="pmc">PMC9126103</ArticleId><ArticleId IdType="pubmed">35606843</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun P., Lu X., Xu C., Sun W., Pan B. Understanding of COVID-19 based on current evidence. J. Med. Virol. 2020;92:548–551. doi: 10.1002/jmv.25722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25722</ArticleId><ArticleId IdType="pmc">PMC7228250</ArticleId><ArticleId IdType="pubmed">32096567</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R., Pei S., Chen B., Song Y., Zhang T., Yang W., Shaman J. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2) Science. 2020;368:489–493. doi: 10.1126/science.abb3221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb3221</ArticleId><ArticleId IdType="pmc">PMC7164387</ArticleId><ArticleId IdType="pubmed">32179701</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727–733. doi: 10.1056/NEJMoa2001017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001017</ArticleId><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchholz U.J., Bukreyev A., Yang L., Lamirande E.W., Murphy B.R., Subbarao K., Collins P.L. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc. Natl. Acad. Sci. USA. 2004;101:9804–9809. doi: 10.1073/pnas.0403492101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0403492101</ArticleId><ArticleId IdType="pmc">PMC470755</ArticleId><ArticleId IdType="pubmed">15210961</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C., Yin W., Jiang Y., Xu H.E. Structure genomics of SARS-CoV-2 and its Omicron variant: Drug design templates for COVID-19. Acta Pharmacol. Sin. 2022;43:3021–3033. doi: 10.1038/s41401-021-00851-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-021-00851-w</ArticleId><ArticleId IdType="pmc">PMC8771608</ArticleId><ArticleId IdType="pubmed">35058587</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y.-W., Schmitz J.E., Persing D.H., Stratton C.W. Laboratory Diagnosis of COVID-19: Current Issues and Challenges. J. Clin. Microbiol. 2020;58:e00512-20. doi: 10.1128/JCM.00512-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00512-20</ArticleId><ArticleId IdType="pmc">PMC7269383</ArticleId><ArticleId IdType="pubmed">32245835</ArticleId></ArticleIdList></Reference><Reference><Citation>Khailany R.A., Safdar M., Ozaslan M. Genomic characterization of a novel SARS-CoV-2. Gene Rep. 2020;19:100682. doi: 10.1016/j.genrep.2020.100682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genrep.2020.100682</ArticleId><ArticleId IdType="pmc">PMC7161481</ArticleId><ArticleId IdType="pubmed">32300673</ArticleId></ArticleIdList></Reference><Reference><Citation>Arshad N., Laurent-Rolle M., Ahmed W.S., Hsu J.C.-C., Mitchell S.M., Pawlak J., Sengupta D., Biswas K.H., Cresswell P. SARS-CoV-2 accessory proteins ORF7a and ORF3a use distinct mechanisms to down-regulate MHC-I surface expression. Proc. Natl. Acad. Sci. USA. 2022;120:e2208525120. doi: 10.1073/pnas.2208525120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2208525120</ArticleId><ArticleId IdType="pmc">PMC9910621</ArticleId><ArticleId IdType="pubmed">36574644</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimoto F.K. The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19. Protein J. 2020;39:198–216. doi: 10.1007/s10930-020-09901-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10930-020-09901-4</ArticleId><ArticleId IdType="pmc">PMC7245191</ArticleId><ArticleId IdType="pubmed">32447571</ArticleId></ArticleIdList></Reference><Reference><Citation>Song F., Fux R., Provacia L.B., Volz A., Eickmann M., Becker S., Osterhaus A.D.M.E., Haagmans B.L., Sutter G. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J. Virol. 2013;87:11950–11954. doi: 10.1128/JVI.01672-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01672-13</ArticleId><ArticleId IdType="pmc">PMC3807317</ArticleId><ArticleId IdType="pubmed">23986586</ArticleId></ArticleIdList></Reference><Reference><Citation>Volz A., Kupke A., Song F., Jany S., Fux R., Shams-Eldin H., Schmidt J., Becker C., Eickmann M., Becker S., et al. Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein. J. Virol. 2015;89:8651–8656. doi: 10.1128/JVI.00614-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00614-15</ArticleId><ArticleId IdType="pmc">PMC4524222</ArticleId><ArticleId IdType="pubmed">26018172</ArticleId></ArticleIdList></Reference><Reference><Citation>Haagmans B.L., van den Brand J.M.A., Raj V.S., Volz A., Wohlsein P., Smits S.L., Schipper D., Bestebroer T.M., Okba N., Fux R., et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science. 2016;351:77–81. doi: 10.1126/science.aad1283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad1283</ArticleId><ArticleId IdType="pubmed">26678878</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch T., Dahlke C., Fathi A., Kupke A., Krähling V., Okba N.M.A., Halwe S., Rohde C., Eickmann M., Volz A., et al. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: An open-label, phase 1 trial. Lancet Infect. Dis. 2020;20:827–838. doi: 10.1016/S1473-3099(20)30248-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30248-6</ArticleId><ArticleId IdType="pmc">PMC7172913</ArticleId><ArticleId IdType="pubmed">32325037</ArticleId></ArticleIdList></Reference><Reference><Citation>Bisht H., Roberts A., Vogel L., Bukreyev A., Collins P.L., Murphy B.R., Subbarao K., Moss B. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc. Natl. Acad. Sci. USA. 2004;101:6641–6646. doi: 10.1073/pnas.0401939101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0401939101</ArticleId><ArticleId IdType="pmc">PMC404098</ArticleId><ArticleId IdType="pubmed">15096611</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiuppesi F., Salazar M.d.A., Contreras H., Nguyen V., Martinez J., Park S., Nguyen J., Kha M., Iniguez A., Zhou Q., et al. Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform. Res. Sq. 2020 doi: 10.21203/rs.3.rs-40198/v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-40198/v1</ArticleId><ArticleId IdType="pmc">PMC7705736</ArticleId><ArticleId IdType="pubmed">33257686</ArticleId></ArticleIdList></Reference><Reference><Citation>Bošnjak B., Odak I., Barros-Martins J., Sandrock I., Hammerschmidt S.I., Permanyer M., Patzer G.E., Greorgiev H., Gutierrez Jauregui R., Tscherne A., et al. Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents. Front. Immunol. 2021;12:772240. doi: 10.3389/fimmu.2021.772240.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.772240</ArticleId><ArticleId IdType="pmc">PMC8632543</ArticleId><ArticleId IdType="pubmed">34858430</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer Zu Natrup C., Tscherne A., Dahlke C., Ciurkiewicz M., Shin D.-L., Fathi A., Rohde C., Kalodimou G., Halwe S., Limpinsel L., et al. Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity. J. Clin. Investig. 2022;132:e159895. doi: 10.1172/JCI159895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI159895</ArticleId><ArticleId IdType="pmc">PMC9754005</ArticleId><ArticleId IdType="pubmed">36301637</ArticleId></ArticleIdList></Reference><Reference><Citation>Tscherne A., Schwarz J.H., Rohde C., Kupke A., Kalodimou G., Limpinsel L., Okba N.M.A., Bošnjak B., Sandrock I., Odak I., et al. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination. Proc. Natl. Acad. Sci. USA. 2021;118:e2026207118. doi: 10.1073/pnas.2026207118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2026207118</ArticleId><ArticleId IdType="pmc">PMC8285915</ArticleId><ArticleId IdType="pubmed">34162739</ArticleId></ArticleIdList></Reference><Reference><Citation>Pérez P., Albericio G., Astorgano D., Flores S., Sánchez-Corzo C., Sánchez-Cordón P.J., Luczkowiak J., Delgado R., Casasnovas J.M., Esteban M., et al. Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates. Front. Immunol. 2023;14:1264323. doi: 10.3389/fimmu.2023.1264323.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1264323</ArticleId><ArticleId IdType="pmc">PMC10754519</ArticleId><ArticleId IdType="pubmed">38155964</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiuppesi F., Nguyen V.H., Park Y., Contreras H., Karpinski V., Faircloth K., Nguyen J., Kha M., Johnson D., Martinez J., et al. Synthetic Multiantigen MVA Vaccine COH04S1 Protects Against SARS-CoV-2 in Syrian Hamsters and Non-Human Primates. bioRxiv. 2021 doi: 10.1038/s41541-022-00436-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-022-00436-6</ArticleId><ArticleId IdType="pmc">PMC8782996</ArticleId><ArticleId IdType="pubmed">35064109</ArticleId></ArticleIdList></Reference><Reference><Citation>Wussow F., Kha M., Kim T., Ly M., Yll-Pico M., Kar S., Lewis M.G., Chiuppesi F., Diamond D.J. Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants. NPJ Vaccines. 2023;8:41. doi: 10.1038/s41541-023-00640-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-023-00640-y</ArticleId><ArticleId IdType="pmc">PMC10018591</ArticleId><ArticleId IdType="pubmed">36928589</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss B., Elroy-Stein O., Mizukami T., Alexander W.A., Fuerst T.R. Product review. New mammalian expression vectors. Nature. 1990;348:91–92. doi: 10.1038/348091a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/348091a0</ArticleId><ArticleId IdType="pubmed">2234068</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter G., Ohlmann M., Erfle V. Non-replicating vaccinia vector efficiently expresses bacteriophage T7 RNA polymerase. FEBS Lett. 1995;371:9–12. doi: 10.1016/0014-5793(95)00843-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(95)00843-X</ArticleId><ArticleId IdType="pubmed">7664891</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyatt L.S., Moss B., Rozenblatt S. Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells. Virology. 1995;210:202–205. doi: 10.1006/viro.1995.1332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1995.1332</ArticleId><ArticleId IdType="pubmed">7793072</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuerst T.R., Niles E.G., Studier F.W., Moss B. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc. Natl. Acad. Sci. USA. 1986;83:8122–8126. doi: 10.1073/pnas.83.21.8122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.83.21.8122</ArticleId><ArticleId IdType="pmc">PMC386879</ArticleId><ArticleId IdType="pubmed">3095828</ArticleId></ArticleIdList></Reference><Reference><Citation>Geissler K., Schneider K., Fleuchaus A., Parrish C.R., Sutter G., Truyen U. Feline calicivirus capsid protein expression and capsid assembly in cultured feline cells. J. Virol. 1999;73:834–838. doi: 10.1128/JVI.73.1.834-838.1999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.73.1.834-838.1999</ArticleId><ArticleId IdType="pmc">PMC103899</ArticleId><ArticleId IdType="pubmed">9847398</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinck G., Birghan C., Harada T., Meyers G., Thiel H.J., Tautz N. A cellular J-domain protein modulates polyprotein processing and cytopathogenicity of a pestivirus. J. Virol. 2001;75:9470–9482. doi: 10.1128/JVI.75.19.9470-9482.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.75.19.9470-9482.2001</ArticleId><ArticleId IdType="pmc">PMC114514</ArticleId><ArticleId IdType="pubmed">11533209</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M.-L., Stollar V. Identification of the amino acid sequence in Sindbis virus nsP4 that binds to the promoter for the synthesis of the subgenomic RNA. Proc. Natl. Acad. Sci. USA. 2004;101:9429–9434. doi: 10.1073/pnas.0400995101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0400995101</ArticleId><ArticleId IdType="pmc">PMC438993</ArticleId><ArticleId IdType="pubmed">15197279</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W., Tian J.-H., Pei Y.-Y., et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–269. doi: 10.1038/s41586-020-2008-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2008-3</ArticleId><ArticleId IdType="pmc">PMC7094943</ArticleId><ArticleId IdType="pubmed">32015508</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y.-N., Chen L.-K., Ma H.-C., Yang H.-H., Li H.-P., Lo S.-Y. Thermal aggregation of SARS-CoV membrane protein. J. Virol. Methods. 2005;129:152–161. doi: 10.1016/j.jviromet.2005.05.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2005.05.022</ArticleId><ArticleId IdType="pmc">PMC7112854</ArticleId><ArticleId IdType="pubmed">16023741</ArticleId></ArticleIdList></Reference><Reference><Citation>van Elslande J., Decru B., Jonckheere S., van Wijngaerden E., Houben E., Vandecandelaere P., Indevuyst C., Depypere M., Desmet S., André E., et al. Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs. Clin. Microbiol. Infect. 2020;26:1557.e1–1557.e7. doi: 10.1016/j.cmi.2020.07.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.07.038</ArticleId><ArticleId IdType="pmc">PMC7834107</ArticleId><ArticleId IdType="pubmed">32745595</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupont L., Snell L.B., Graham C., Seow J., Merrick B., Lechmere T., Maguire T.J.A., Hallett S.R., Pickering S., Charalampous T., et al. Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. Nat. Microbiol. 2021;6:1433–1442. doi: 10.1038/s41564-021-00974-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-021-00974-0</ArticleId><ArticleId IdType="pmc">PMC8556155</ArticleId><ArticleId IdType="pubmed">34654917</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenwick C., Croxatto A., Coste A.T., Pojer F., André C., Pellaton C., Farina A., Campos J., Hacker D., Lau K., et al. Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies. J. Virol. 2021;95:e01828-20. doi: 10.1128/JVI.01828-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01828-20</ArticleId><ArticleId IdType="pmc">PMC7925109</ArticleId><ArticleId IdType="pubmed">33144321</ArticleId></ArticleIdList></Reference><Reference><Citation>Solastie A., Virta C., Haveri A., Ekström N., Kantele A., Miettinen S., Lempainen J., Jalkanen P., Kakkola L., Dub T., et al. A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies. Microbiol. Spectr. 2021;9:e0113121. doi: 10.1128/Spectrum.01131-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/Spectrum.01131-21</ArticleId><ArticleId IdType="pmc">PMC8597651</ArticleId><ArticleId IdType="pubmed">34787485</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares S.R., Da Silva Torres M.K., Lima S.S., de Sarges K.M.L., Santos E.F.D., de Brito M.T.F.M., Da Silva A.L.S., de Meira Leite M., Da Costa F.P., Cantanhede M.H.D., et al. Antibody Response to the SARS-CoV-2 Spike and Nucleocapsid Proteins in Patients with Different COVID-19 Clinical Profiles. Viruses. 2023;15:898. doi: 10.3390/v15040898.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15040898</ArticleId><ArticleId IdType="pmc">PMC10141342</ArticleId><ArticleId IdType="pubmed">37112878</ArticleId></ArticleIdList></Reference><Reference><Citation>Clever S., Schünemann L.-M., Armando F., Meyer Zu Natrup C., Tuchel T., Tscherne A., Ciurkiewicz M., Baumgärtner W., Sutter G., Volz A. Protective MVA-ST Vaccination Robustly Activates T Cells and Antibodies in an Aged-Hamster Model for COVID-19. Vaccines. 2024;12:52. doi: 10.3390/vaccines12010052.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12010052</ArticleId><ArticleId IdType="pmc">PMC10819389</ArticleId><ArticleId IdType="pubmed">38250865</ArticleId></ArticleIdList></Reference><Reference><Citation>Clever S., Limpinsel L., Meyer Zu Natrup C., Schünemann L.-M., Beythien G., Rosiak M., Hülskötter K., Gregor K.M., Tuchel T., Kalodimou G., et al. Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge Infection. Viruses. 2024;16:417. doi: 10.3390/v16030417.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v16030417</ArticleId><ArticleId IdType="pmc">PMC10974247</ArticleId><ArticleId IdType="pubmed">38543782</ArticleId></ArticleIdList></Reference><Reference><Citation>Pajot A., Michel M.-L., Fazilleau N., Pancré V., Auriault C., Ojcius D.M., Lemonnier F.A., Lone Y.-C. A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice. Eur. J. Immunol. 2004;34:3060–3069. doi: 10.1002/eji.200425463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.200425463</ArticleId><ArticleId IdType="pubmed">15468058</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyatt L.S., Earl P.L., Xiao W., Americo J.L., Cotter C.A., Vogt J., Moss B. Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection. J. Virol. 2009;83:7176–7184. doi: 10.1128/JVI.00687-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00687-09</ArticleId><ArticleId IdType="pmc">PMC2704791</ArticleId><ArticleId IdType="pubmed">19420086</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyatt L.S., Shors S.T., Murphy B.R., Moss B. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine. 1996;14:1451–1458. doi: 10.1016/S0264-410X(96)00072-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(96)00072-2</ArticleId><ArticleId IdType="pubmed">8994321</ArticleId></ArticleIdList></Reference><Reference><Citation>Ureta-Vidal A., Firat H., Pérarnau B., Lemonnier F.A. Phenotypical and functional characterization of the CD8+ T cell repertoire of HLA-A2.1 transgenic, H-2KbnullDbnull double knockout mice. J. Immunol. 1999;163:2555–2560. doi: 10.4049/jimmunol.163.5.2555.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.163.5.2555</ArticleId><ArticleId IdType="pubmed">10452993</ArticleId></ArticleIdList></Reference><Reference><Citation>Dion S., Bourgine M., Godon O., Levillayer F., Michel M.-L. Adeno-associated virus-mediated gene transfer leads to persistent hepatitis B virus replication in mice expressing HLA-A2 and HLA-DR1 molecules. J. Virol. 2013;87:5554–5563. doi: 10.1128/JVI.03134-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03134-12</ArticleId><ArticleId IdType="pmc">PMC3648192</ArticleId><ArticleId IdType="pubmed">23468504</ArticleId></ArticleIdList></Reference><Reference><Citation>Volz A., Lim S., Kaserer M., Lülf A., Marr L., Jany S., Deeg C.A., Pijlman G.P., Koraka P., Osterhaus A.D.M.E., et al. Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens. Vaccine. 2016;34:1915–1926. doi: 10.1016/j.vaccine.2016.02.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.02.042</ArticleId><ArticleId IdType="pubmed">26939903</ArticleId></ArticleIdList></Reference><Reference><Citation>Saini S.K., Hersby D.S., Tamhane T., Povlsen H.R., Amaya Hernandez S.P., Nielsen M., Gang A.O., Hadrup S.R. SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8+ T cell activation in COVID-19 patients. Sci. Immunol. 2021;6:eabf7550. doi: 10.1126/sciimmunol.abf7550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abf7550</ArticleId><ArticleId IdType="pmc">PMC8139428</ArticleId><ArticleId IdType="pubmed">33853928</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin X., Liu X., Shen C. A systemic review of T-cell epitopes defined from the proteome of SARS-CoV-2. Virus Res. 2022;324:199024. doi: 10.1016/j.virusres.2022.199024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2022.199024</ArticleId><ArticleId IdType="pmc">PMC9757803</ArticleId><ArticleId IdType="pubmed">36526016</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J., Law R., Korosec C.S., Zhou C., Koh W.H., Ghaemi M.S., Samaan P., Ooi H.K., Matveev V., Yue F., et al. Longitudinal Assessment of SARS-CoV-2-Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multicytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity. J. Virol. 2022;96:e0050922. doi: 10.1128/jvi.00509-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00509-22</ArticleId><ArticleId IdType="pmc">PMC9278147</ArticleId><ArticleId IdType="pubmed">35699447</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller M.D., Harris K.M., Jensen-Wachspress M.A., Kankate V.V., Lang H., Lazarski C.A., Durkee-Shock J., Lee P.-H., Chaudhry K., Webber K., et al. SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein. Blood. 2020;136:2905–2917. doi: 10.1182/blood.2020008488.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020008488</ArticleId><ArticleId IdType="pmc">PMC7746091</ArticleId><ArticleId IdType="pubmed">33331927</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasquetto V., Bui H.-H., Giannino R., Banh C., Mirza F., Sidney J., Oseroff C., Tscharke D.C., Irvine K., Bennink J.R., et al. HLA-A*0201, HLA-A*1101, and HLA-B*0702 transgenic mice recognize numerous poxvirus determinants from a wide variety of viral gene products. J. Immunol. 2005;175:5504–5515. doi: 10.4049/jimmunol.175.8.5504.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.175.8.5504</ArticleId><ArticleId IdType="pubmed">16210659</ArticleId></ArticleIdList></Reference><Reference><Citation>Algaissi A., Alfaleh M.A., Hala S., Abujamel T.S., Alamri S.S., Almahboub S.A., Alluhaybi K.A., Hobani H.I., Alsulaiman R.M., AlHarbi R.H., et al. SARS-CoV-2 S1 and N-based serological assays reveal rapid seroconversion and induction of specific antibody response in COVID-19 patients. Sci. Rep. 2020;10:16561. doi: 10.1038/s41598-020-73491-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-73491-5</ArticleId><ArticleId IdType="pmc">PMC7538990</ArticleId><ArticleId IdType="pubmed">33024213</ArticleId></ArticleIdList></Reference><Reference><Citation>Burbelo P.D., Riedo F.X., Morishima C., Rawlings S., Smith D., Das S., Strich J.R., Chertow D.S., Davey R.T., Cohen J.I. Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients with Coronavirus Disease 2019. J. Infect. Dis. 2020;222:206–213. doi: 10.1093/infdis/jiaa273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa273</ArticleId><ArticleId IdType="pmc">PMC7313936</ArticleId><ArticleId IdType="pubmed">32427334</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfego D., Sullivan A., Poirier B., Williams J., Adcock D., Letovsky S. A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States. eClinicalMedicine. 2021;36:100902. doi: 10.1016/j.eclinm.2021.100902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.100902</ArticleId><ArticleId IdType="pmc">PMC8143650</ArticleId><ArticleId IdType="pubmed">34056568</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W., Liu L., Kou G., Zheng Y., Ding Y., Ni W., Wang Q., Tan L., Wu W., Tang S., et al. Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2. J. Clin. Microbiol. 2020;58:e00461-20. doi: 10.1128/JCM.00461-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00461-20</ArticleId><ArticleId IdType="pmc">PMC7269413</ArticleId><ArticleId IdType="pubmed">32229605</ArticleId></ArticleIdList></Reference><Reference><Citation>van Elslande J., Oyaert M., Lorent N., Vande Weygaerde Y., van Pottelbergh G., Godderis L., van Ranst M., André E., Padalko E., Lagrou K., et al. Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection. Diagn. Microbiol. Infect. Dis. 2022;103:115659. doi: 10.1016/j.diagmicrobio.2022.115659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diagmicrobio.2022.115659</ArticleId><ArticleId IdType="pmc">PMC8837483</ArticleId><ArticleId IdType="pubmed">35278794</ArticleId></ArticleIdList></Reference><Reference><Citation>Dispinseri S., Secchi M., Pirillo M.F., Tolazzi M., Borghi M., Brigatti C., de Angelis M.L., Baratella M., Bazzigaluppi E., Venturi G., et al. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. Nat. Commun. 2021;12:2670. doi: 10.1038/s41467-021-22958-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-22958-8</ArticleId><ArticleId IdType="pmc">PMC8113594</ArticleId><ArticleId IdType="pubmed">33976165</ArticleId></ArticleIdList></Reference><Reference><Citation>Siu Y.L., Teoh K.T., Lo J., Chan C.M., Kien F., Escriou N., Tsao S.W., Nicholls J.M., Altmeyer R., Peiris J.S.M., et al. The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles. J. Virol. 2008;82:11318–11330. doi: 10.1128/JVI.01052-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01052-08</ArticleId><ArticleId IdType="pmc">PMC2573274</ArticleId><ArticleId IdType="pubmed">18753196</ArticleId></ArticleIdList></Reference><Reference><Citation>Fehr A.R., Perlman S. Coronaviruses: An overview of their replication and pathogenesis. Methods Mol. Biol. 2015;1282:1–23. doi: 10.1007/978-1-4939-2438-7_1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-2438-7_1</ArticleId><ArticleId IdType="pmc">PMC4369385</ArticleId><ArticleId IdType="pubmed">25720466</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng R., Yang R.-F., Shi M.-D., Jiang M.-R., Xie Y.-H., Ruan H.-Q., Jiang X.-S., Shi L., Zhou H., Zhang L., et al. Characterization of the 3a protein of SARS-associated coronavirus in infected vero E6 cells and SARS patients. J. Mol. Biol. 2004;341:271–279. doi: 10.1016/j.jmb.2004.06.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2004.06.016</ArticleId><ArticleId IdType="pmc">PMC7127270</ArticleId><ArticleId IdType="pubmed">15312778</ArticleId></ArticleIdList></Reference><Reference><Citation>Du L., He Y., Zhou Y., Liu S., Zheng B.-J., Jiang S. The spike protein of SARS-CoV—A target for vaccine and therapeutic development. Nat. Rev. Microbiol. 2009;7:226–236. doi: 10.1038/nrmicro2090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro2090</ArticleId><ArticleId IdType="pmc">PMC2750777</ArticleId><ArticleId IdType="pubmed">19198616</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D., Zheng Q., Sun L., Ji M., Li Y., Deng H., Zhang H. ORF3a of SARS-CoV-2 promotes lysosomal exocytosis-mediated viral egress. Dev. Cell. 2021;56:3250–3263.e5. doi: 10.1016/j.devcel.2021.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2021.10.006</ArticleId><ArticleId IdType="pmc">PMC8502680</ArticleId><ArticleId IdType="pubmed">34706264</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue Y., Nabar N.R., Shi C.-S., Kamenyeva O., Xiao X., Hwang I.-Y., Wang M., Kehrl J.H. SARS-Coronavirus Open Reading Frame-3a drives multimodal necrotic cell death. Cell Death Dis. 2018;9:904. doi: 10.1038/s41419-018-0917-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-018-0917-y</ArticleId><ArticleId IdType="pmc">PMC6125346</ArticleId><ArticleId IdType="pubmed">30185776</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu W., Zheng B.-J., Xu K., Schwarz W., Du L., Wong C.K.L., Chen J., Duan S., Deubel V., Sun B. Severe acute respiratory syndrome-associated coronavirus 3a protein forms an ion channel and modulates virus release. Proc. Natl. Acad. Sci. USA. 2006;103:12540–12545. doi: 10.1073/pnas.0605402103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0605402103</ArticleId><ArticleId IdType="pmc">PMC1567914</ArticleId><ArticleId IdType="pubmed">16894145</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R., Yang X., Chang M., Xue Z., Wang W., Bai L., Zhao S., Liu E. ORF3a Protein of Severe Acute Respiratory Syndrome Coronavirus 2 Inhibits Interferon-Activated Janus Kinase/Signal Transducer and Activator of Transcription Signaling via Elevating Suppressor of Cytokine Signaling 1. Front. Microbiol. 2021;12:752597. doi: 10.3389/fmicb.2021.752597.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.752597</ArticleId><ArticleId IdType="pmc">PMC8506155</ArticleId><ArticleId IdType="pubmed">34650546</ArticleId></ArticleIdList></Reference><Reference><Citation>Castaño-Rodriguez C., Honrubia J.M., Gutiérrez-Álvarez J., DeDiego M.L., Nieto-Torres J.L., Jimenez-Guardeño J.M., Regla-Nava J.A., Fernandez-Delgado R., Verdia-Báguena C., Queralt-Martín M., et al. Role of Severe Acute Respiratory Syndrome Coronavirus Viroporins E, 3a, and 8a in Replication and Pathogenesis. mBio. 2018;9:e02325-17. doi: 10.1128/mBio.02325-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.02325-17</ArticleId><ArticleId IdType="pmc">PMC5964350</ArticleId><ArticleId IdType="pubmed">29789363</ArticleId></ArticleIdList></Reference><Reference><Citation>Siu K.-L., Yuen K.-S., Castaño-Rodriguez C., Ye Z.-W., Yeung M.-L., Fung S.-Y., Yuan S., Chan C.-P., Yuen K.-Y., Enjuanes L., et al. Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC. FASEB J. 2019;33:8865–8877. doi: 10.1096/fj.201802418R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201802418R</ArticleId><ArticleId IdType="pmc">PMC6662968</ArticleId><ArticleId IdType="pubmed">31034780</ArticleId></ArticleIdList></Reference><Reference><Citation>Camerini D., Randall A.Z., Trappl-Kimmons K., Oberai A., Hung C., Edgar J., Shandling A., Huynh V., Teng A.A., Hermanson G., et al. Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray. Microbiol. Spectr. 2021;9:e0141621. doi: 10.1128/Spectrum.01416-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/Spectrum.01416-21</ArticleId><ArticleId IdType="pmc">PMC8549749</ArticleId><ArticleId IdType="pubmed">34704808</ArticleId></ArticleIdList></Reference><Reference><Citation>Amanat F., Stadlbauer D., Strohmeier S., Nguyen T.H.O., Chromikova V., McMahon M., Jiang K., Arunkumar G.A., Jurczyszak D., Polanco J., et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 2020;26:1033–1036. doi: 10.1038/s41591-020-0913-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0913-5</ArticleId><ArticleId IdType="pmc">PMC8183627</ArticleId><ArticleId IdType="pubmed">32398876</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadweh P., Orfanidou T., Tsiamita M., Timologos G., Papadopoulos T. SARS-CoV2: Diagnostic tests available to the clinician. Hell. J. Nucl. Med. 2020;23:8–14.</Citation><ArticleIdList><ArticleId IdType="pubmed">32860390</ArticleId></ArticleIdList></Reference><Reference><Citation>Bubonja-Šonje M., Batičić L., Abram M., Cekinović Grbeša Đ. Diagnostic accuracy of three SARS-CoV2 antibody detection assays, neutralizing effect and longevity of serum antibodies. J. Virol. Methods. 2021;293:114173. doi: 10.1016/j.jviromet.2021.114173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2021.114173</ArticleId><ArticleId IdType="pmc">PMC8078047</ArticleId><ArticleId IdType="pubmed">33930473</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes Q., Inchakalody V.P., Merhi M., Mestiri S., Taib N., Moustafa Abo El-Ella D., Bedhiafi T., Raza A., Al-Zaidan L., Mohsen M.O., et al. Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. Ann. Med. 2022;54:524–540. doi: 10.1080/07853890.2022.2031274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2022.2031274</ArticleId><ArticleId IdType="pmc">PMC8843115</ArticleId><ArticleId IdType="pubmed">35132910</ArticleId></ArticleIdList></Reference><Reference><Citation>Auerswald H., Eng C., Lay S., In S., Eng S., Vo H.T.M., Sith C., Cheng S., Delvallez G., Mich V., et al. Rapid Generation of In-House Serological Assays Is Comparable to Commercial Kits Critical for Early Response to Pandemics: A Case with SARS-CoV-2. Front. Med. 2022;9:864972. doi: 10.3389/fmed.2022.864972.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.864972</ArticleId><ArticleId IdType="pmc">PMC9121123</ArticleId><ArticleId IdType="pubmed">35602487</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavia C.S., Wormser G.P. COVID-19: Is there a role for Western blots and skin testing for determining immunity and development of a vaccine? Diagn. Microbiol. Infect. Dis. 2020;98:115148. doi: 10.1016/j.diagmicrobio.2020.115148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diagmicrobio.2020.115148</ArticleId><ArticleId IdType="pmc">PMC7424330</ArticleId><ArticleId IdType="pubmed">32920452</ArticleId></ArticleIdList></Reference><Reference><Citation>Kremer M., Volz A., Kreijtz J.H.C.M., Fux R., Lehmann M.H., Sutter G. Easy and efficient protocols for working with recombinant vaccinia virus MVA. Methods Mol. Biol. 2012;890:59–92. doi: 10.1007/978-1-61779-876-4_4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-61779-876-4_4</ArticleId><ArticleId IdType="pubmed">22688761</ArticleId></ArticleIdList></Reference><Reference><Citation>Özçürümez M.K., Ambrosch A., Frey O., Haselmann V., Holdenrieder S., Kiehntopf M., Neumaier M., Walter M., Wenzel F., Wölfel R., et al. SARS-CoV-2 antibody testing-questions to be asked. J. Allergy Clin. Immunol. 2020;146:35–43. doi: 10.1016/j.jaci.2020.05.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.05.020</ArticleId><ArticleId IdType="pmc">PMC7256507</ArticleId><ArticleId IdType="pubmed">32479758</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalodimou G., Veit S., Jany S., Kalinke U., Broder C.C., Sutter G., Volz A. A Soluble Version of Nipah Virus Glycoprotein G Delivered by Vaccinia Virus MVA Activates Specific CD8 and CD4 T Cells in Mice. Viruses. 2019;12:26. doi: 10.3390/v12010026.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12010026</ArticleId><ArticleId IdType="pmc">PMC7019319</ArticleId><ArticleId IdType="pubmed">31878180</ArticleId></ArticleIdList></Reference><Reference><Citation>Backes S., Sperling K.M., Zwilling J., Gasteiger G., Ludwig H., Kremmer E., Schwantes A., Staib C., Sutter G. Viral host-range factor C7 or K1 is essential for modified vaccinia virus Ankara late gene expression in human and murine cells, irrespective of their capacity to inhibit protein kinase R-mediated phosphorylation of eukaryotic translation initiation factor 2α. J. Gen. Virol. 2010;91:470–482.</Citation><ArticleIdList><ArticleId IdType="pubmed">19846675</ArticleId></ArticleIdList></Reference><Reference><Citation>Kared H., Redd A.D., Bloch E.M., Bonny T.S., Sumatoh H., Kairi F., Carbajo D., Abel B., Newell E.W., Bettinotti M.P., et al. ARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 individuals. J. Clin. Investig. 2021;131 doi: 10.1172/JCI145476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI145476</ArticleId><ArticleId IdType="pmc">PMC7919723</ArticleId><ArticleId IdType="pubmed">33427749</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>